14 results on '"Berkkan, Metehan"'
Search Results
2. Post-acute COVID-19 syndrome and kidney diseases: what do we know?
- Author
-
Copur, Sidar, Berkkan, Metehan, Basile, Carlo, Tuttle, Katherine, and Kanbay, Mehmet
- Published
- 2022
- Full Text
- View/download PDF
3. Intensive blood pressure control on dementia in patients with chronic kidney disease: Potential reduction in disease burden
- Author
-
Copur, Sidar, Berkkan, Metehan, Sarafidis, Pantelis, and Kanbay, Mehmet
- Published
- 2022
- Full Text
- View/download PDF
4. Dialysis in Pregnancy: An Update Review.
- Author
-
Copur, Sidar, Berkkan, Metehan, Basile, Carlo, Cozzolino, Mario, and Kanbay, Mehmet
- Subjects
- *
RENAL replacement therapy , *CHRONIC kidney failure , *THIRD trimester of pregnancy , *DIALYSIS (Chemistry) , *HEMODIALYSIS , *CALCIPHYLAXIS - Abstract
Chronic kidney disease and end-stage kidney disease (ESKD) are important public health problems with increased rates of morbidity, mortality, and social costs. Pregnancy is rare in patients with ESKD, with reduced fertility rates in women undergoing dialysis. Although current advances have led to an increase in live births in pregnant dialysis patients, this modality still has an increased risk of multiple adverse events in pregnant women. Despite these existing risks, large-scale studies investigating the management of pregnant women on dialysis are lacking, resulting in the absence of consensus guidelines for this patient group. In this review, we aimed to present the effects of dialysis during pregnancy. We first discuss pregnancy outcomes in dialysis patients and the development of acute kidney injury during pregnancy. Then, we discuss our recommendations for the management of pregnant dialysis patients, including the maintenance of pre-dialysis blood urea nitrogen levels, the ideal frequency and duration of hemodialysis sessions, as well as the modality of renal replacement therapies, the difficulty of maintaining peritoneal dialysis in the third trimester of pregnancy, and optimization of prepregnancy modifiable risk factors. Finally, we present our recommendations for future studies investigating dialysis among pregnant patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
- Author
-
Kanbay, Mehmet, Copur, Sidar, Siriopol, Dimitrie, Yildiz, Abdullah Burak, Berkkan, Metehan, Popa, Raluca, Hasbal, Nuri Baris, Ortiz, Alberto, and Perazella, Mark A
- Subjects
IMMUNE checkpoint inhibitors ,ACUTE kidney failure ,CANCER prognosis ,IPILIMUMAB ,CANCER-related mortality ,CANCER treatment - Abstract
Background Immune checkpoint inhibitors (ICPIs) are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, we assessed the effect of AKI on mortality outcomes in cancer patients receiving this immunotherapy. Methods We performed a systematic review and meta-analysis of prospective, retrospective, randomized and non-randomized studies, which examined the effects of AKI in cancer patients receiving immune checkpoint inhibitors. We searched through PubMed, Medline, Web of Science, Scopus and Cochrane Library databases. Results Seven studies were included in the final analysis, with a total number of patients of 761. Overall, the risk of death was higher in patients that developed AKI during ICPI treatment [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.05–1.92, P = 0.02; heterogeneity χ
2 = 11.68, I2 = 66%, P = 0.02] compared with patients that did not develop AKI. In addition, there was a trend to a better survival in those with less severe AKI patients compared with those with more severe AKI (HR 1.35, 95% CI 0.99–1.83, P = 0.05). Lastly, it was seen that patients with persistent kidney dysfunction (non-recovery) had an increased risk for all-cause mortality (HR 2.93, 95% CI 1.41–6.08, P = 0.004; heterogeneity χ2 = 0.53, I2 = 0%, P = 0.47). Conclusions Development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. The risk for chronic kidney disease in metabolically healthy obese patients: A systematic review and meta‐analysis.
- Author
-
Kanbay, Mehmet, Copur, Sidar, Siriopol, Dimitrie, Yildiz, Abdullah B., Berkkan, Metehan, Tuttle, Kathherine R., and Zoccali, Carmine
- Subjects
CHRONIC kidney failure ,DISEASE risk factors ,OBESITY ,METABOLIC syndrome ,HDL cholesterol - Abstract
Background: Chronic kidney disease (CKD) is associated with obesity and metabolic syndrome. Nevertheless, the association of CKD with phenotype referred as metabolically healthy obese or overweight is unclear. In this this systematic review and meta‐analysis, we investigate the relationships between obesity and CKD independent of metabolic syndrome by appraising published evidence in studies focusing on metabolically healthy obese people. Materials and Methods: We performed a literature search through three databases Embase (Elsevier), the Cochrane Central Register of Controlled Trials (Wiley) and PubMed/Medline Web of Science up to March 2022 with the following terms: "chronic kidney disease", "kidney function", "obesity", "metabolic syndrome", "metabolically healthy obesity", "metabolically healthy overweight". Metabolically unhealthy was defined an individual having at least 3 of the following: abdominal obesity, high blood pressure, hypertriglyceridemia, low HDL cholesterol and hyperglycaemia. We used Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) for reporting. Prospective, retrospective, randomized and nonrandomized studies fitting the search criteria were included in our results. Results: Our final analysis included 16 studies with a total number of 4.965.285 participants. There is considerable heterogeneity in terms of study design, participant characteristics and number of participants across individual studies. In comparison to healthy normal weight patients, the risk was progressively higher in overweight (RR 1.29, 95% CI 1.27 to 1.32, p < 0.001) and obese patients (RR 1.47, 95% CI 1.31 to 1.65, p < 0.001). Conclusion: Metabolically healthy overweight and obese individuals have higher risk of CKD compared to individuals without weight excess. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Neutralizing antibody levels and cellular immune response against Omicron variant in pregnant women vaccinated with mRNA and inactivated SARS‐CoV‐2 vaccines.
- Author
-
Kalafat, E., Talay, Z. Gülçe, Demirci, O., Ayaz, R., Çelik, E., Can, F., Berkkan, Metehan, Esken, Gulen Güney, Ünal, Ceren, Barlas, Tayfun, Güler, Sebile Çekiç, Alatas, Cengiz, Urman, Bulent, Ayhan, Işıl, Aydın, Emine, Şahin, Orhan, Bulat, Hanne, İncir, Said, and Doğan, Özlem
- Subjects
SARS-CoV-2 Omicron variant ,HUMORAL immunity ,COVID-19 vaccines ,PREGNANT women ,SARS-CoV-2 ,VACCINATION - Abstract
A study investigated the immune response of pregnant women vaccinated with mRNA and inactivated SARS-CoV-2 vaccines against the Omicron variant. The results showed that pregnant women who received the mRNA vaccine had higher neutralizing antibody levels against both the Wuhan and Omicron variants compared to those who received the inactivated vaccine. However, neutralizing antibody activity against the Omicron variant was lower compared to the Wuhan variant for both vaccine types. The study suggests the importance of booster shots and new-generation vaccines targeted against variants of concern. The choice of vaccine type for booster shots may be based on regional availability rather than efficacy data in pregnant women. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
8. Benefits and Drawbacks of Continuous Glucose Monitoring (CGM) Use in Young Children With Type 1 Diabetes: A Qualitative Study From a Country Where the CGM Is Not Reimbursed.
- Author
-
Karakuş, Kağan Ege, Sakarya, Sibel, Yeşiltepe Mutlu, Gül, Berkkan, Metehan, Muradoğlu, Serra, Can, Ecem, Gökçe, Tuğba, Eviz, Elif, and Hatun, Şükrü
- Published
- 2021
- Full Text
- View/download PDF
9. EFFECT OF HEMOSTATIC METHODS USED IN LAPAROSCOPIC SURGERY FOR OVARIAN ENDOMETRIOMA ON OVARIAN RESERVE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED TRIALS.
- Author
-
Kalafat, Erkan, Aslan, Batuhan, Berkkan, Metehan, Sonmezer, Murat, Atabekoglu, Cem Somer, and Ata, Baris
- Subjects
- *
OVARIAN reserve , *LAPAROSCOPIC surgery , *ENDOMETRIOSIS - Published
- 2022
- Full Text
- View/download PDF
10. Efficacy of Amikacin and Meropenem on Colistin-Induced Klebsiella pneumoniae Persisters.
- Author
-
Vatansever, Cansel, Ozer, Berna, Atac, Nazlı, Guler, Orhan Ulas, Kilicoglu, Bilge Kaan, Berkkan, Metehan, Baskurt, Defne, Sever, Egemen, Dogan, Ozlem, and Can, Fusun
- Subjects
- *
AMIKACIN , *MEROPENEM , *KLEBSIELLA pneumoniae , *COLISTIN , *KLEBSIELLA infections , *ANTIBIOTICS - Abstract
Colistin-based antibiotic therapies have been recommended for the treatment of multidrug-resistant Klebsiella pneumoniae infections. During colistin treatment, persister cells that tolerate antibiotics may arise. Here we designed an in vitro study to assess the killing activity of colistin, meropenem, and amikacin on colistin-induced K. pneumoniae persisters in comparison with starvation-induced persisters. Colistin-induced persisters were generated under exposure to 10 × minimum inhibitory concentration dose of colistin, whereas starvation-induced persisters were produced by limitation of nutrients. In colistin-induced persisters, amikacin totally inhibited cell growth in 6 hours, whereas 98% of the cell population was inhibited by meropenem, and total eradication with meropenem was observed after 24 hours. Both antibiotics also inhibited metabolic activity >88%. The lack of killing effect under colistin exposure suggested to us that these cells could protect themselves from further colistin stress. There was no significant permeabilization change in the cellular membrane with all antibiotics. There was no killing effect on starvation-induced persister cells with the exposure to all antibiotics. In 6 hours, the metabolic activity of the persisters with meropenem and colistin increased 99% and 40%, respectively, whereas there was no increase with amikacin. The sustained inhibition with amikacin was an important finding for antipersister effect of amikacin. Amikacin had rapid and sustained antipersister activity on colistin-induced persister cells. During the colistin treatment of K. pneumoniae infection, the addition of amikacin to the regimen seems to be an effective approach to prevent a recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
- Author
-
Kanbay, Mehmet (ORCID 0000-0002-1297-0675 & YÖK ID 110580), Çöpür, Sidar (ORCID 0000-0003-0190-2746 & YÖK ID 368625), Yıldız, Abdullah Burak, Berkkan, Metehan, Hasbal, Nuri Barış, Siriopol, Dimitrie, Popa, Raluca, Ortiz, Alberto, Perazella, Mark A., Koç University Hospital, and School of Medicine
- Subjects
Acute kidney injury ,Acute renal failure ,Immune checkpoint inhibitors ,Immunotherapy ,Nephrotoxicity ,Urology and nephrology - Abstract
Lay summary: immune checkpoint inhibitors are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality. Background: immune checkpoint inhibitors (ICPIs) are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, we assessed the effect of AKI on mortality outcomes in cancer patients receiving this immunotherapy. Methods: we performed a systematic review and meta-analysis of prospective, retrospective, randomized and non-randomized studies, which examined the effects of AKI in cancer patients receiving immune checkpoint inhibitors. We searched through PubMed, Medline, Web of Science, Scopus, and Cochrane Library databases. Results: seven studies were included in the final analysis, with a total number of patients of 761. Overall, the risk of death was higher in patients that developed AKI during ICPI treatment [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.05-1.92, P = 0.02; heterogeneity chi(2) = 11.68, I-2 = 66%, P = 0.02] compared with patients that did not develop AKI. In addition, there was a trend to a better survival in those with less severe AKI patients compared with those with more severe AKI (HR 1.35, 95% CI 0.99-1.83, P = 0.05). Lastly, it was seen that patients with persistent kidney dysfunction (non-recovery) had an increased risk for all-cause mortality (HR 2.93, 95% CI 1.41-6.08, P = 0.004; heterogeneity chi(2) = 0.53, I-2 = 0%, P = 0.47). Conclusions: development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality., NA
- Published
- 2023
12. Post-acute COVID-19 syndrome and kidney diseases: what do we know?
- Author
-
Kanbay, Mehmet (ORCID 0000-0002-1297-0675 & YÖK ID 110580), Çöpür, Sidar, Berkkan, Metehan, Basile, Carlo, Tuttle, Katherine, and School of Medicine
- Subjects
Urology and nephrology ,Acute kidney injury ,Chronic kidney disease ,COVID-19 ,End-stage kidney disease ,Post-acute COVID-19 syndrome - Abstract
COVID-19, a disease caused by a novel coronavirus (SARS-CoV-2), is a major global threat that has turned into a pandemic. Despite the emergence of multiple vaccination alternatives and developing therapeutic options, dramatic short- and long-term clinical outcomes have been recorded with more than 250 million infected people and over 5 million deaths as of November 2021. COVID-19 presents various respiratory, cardiovascular, neuropsychiatric, musculoskeletal and kidney features during the acute phase; nevertheless, renal involvement in the post-infection period has recently been emphasized. The present review aims to evaluate the growing literature on kidney involvement in the SARS-CoV-2 infection along with clinical features reported both in the acute phase of the infection and in the post-acute COVID-19 period by assessing potential pathophysiological frameworks explaining such conditions. Chronic kidney disease and development of acute kidney injury (AKI) in the course of initial hospitalization are associated with high mortality and morbidity rates. Moreover, growing evidence suggests a decline in renal function in the 6-to-12-month follow-up period even in patients without any signs of AKI during the acute phase. Despite such concerns there are no guidelines regulating the follow-up period or therapeutic alternatives for such patient population. In conclusion, the burden of COVID-19 on the kidney is yet to be determined. Future prospective large scale studies are needed with long follow-up periods assessing kidney involvement via multiple parameters such as biopsy studies, urinalysis, measurement of serum creatinine and cystatin C, directly measured glomerular filtration rate, and assessment of tubular function via urinary beta(2)-microglobulin measurements., NA
- Published
- 2022
13. Benefits and drawbacks of Continuous Glucose Monitoring (CGM) use in young children with type 1 diabetes: a qualitative study from a country where the CGM is not reimbursed
- Author
-
Kağan Ege Karakuş, Sibel Sakarya, Gül Yeşiltepe Mutlu, Metehan Berkkan, Serra Muradoğlu, Ecem Can, Tuğba Gökçe, Elif Eviz, Şükrü Hatun, Karakuş, Kağan Ege, Sakarya, Sibel (ORCID 0000-0002-9959-6240 & YÖK ID 172028), Mutlu, Gül Yeşiltepe (ORCID 0000-0003-3919-7763 & YÖK ID 153511), Berkkan, Metehan, Muradoğlu, Serra, Can, Ecem, Gökçe, Tuğba, Eviz, Elif (ORCID 0000-0002-8889-6811 & YÖK ID 327618), Hatun, Şükrü (ORCID 0000-0003-1633-9570 & YÖK ID 153504), Koç University Hospital, School of Medicine, and Graduate School of Health Sciences
- Subjects
young children ,Medicine (General) ,Type 1 diabetes ,Continuous glucose monitoring ,Qualitative methods ,Family experiences ,Young children ,Health (social science) ,endocrine system diseases ,Leadership and Management ,Health Policy ,nutritional and metabolic diseases ,R5-920 ,continuous glucose monitoring ,Health care sciences and services ,family experiences ,Research Article ,qualitative methods - Abstract
Investigating the daily life experiences of patients using Continuous Glucose Monitoring (CGM) can highlight the benefits and barriers in using this system for people with type 1 diabetes (T1D). Semi-structured qualitative interviews were conducted with the caregivers of 10 children aged 6 months. These interviews were analyzed using the content analysis approach and from these interviews, four meta themes emerged: metabolic control, barriers to CGM use, CGM use in daily life, and comparison with fingersticks. Families reported the following as benefits of CGM: pain relief, better hypoglycemia and hyperglycemia management, increased control over diet and social life, reduced worries at school and during the night, and convenience in entrusting the child to the care of others. Cost, concerns related to accuracy and reliability of measurements, insertion, adhesion and removal issues all emerged as barriers to CGM use. The most prominent issue was the economic burden of CGM. Families accept this burden, even though it is challenging, as their experiences in using CGM are positive and they feel that CGM is necessary for T1D management., NA
- Published
- 2021
14. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
- Author
-
Kanbay M, Copur S, Siriopol D, Yildiz AB, Berkkan M, Popa R, Hasbal NB, Ortiz A, and Perazella MA
- Abstract
Background: Immune checkpoint inhibitors (ICPIs) are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, we assessed the effect of AKI on mortality outcomes in cancer patients receiving this immunotherapy., Methods: We performed a systematic review and meta-analysis of prospective, retrospective, randomized and non-randomized studies, which examined the effects of AKI in cancer patients receiving immune checkpoint inhibitors. We searched through PubMed, Medline, Web of Science, Scopus and Cochrane Library databases., Results: Seven studies were included in the final analysis, with a total number of patients of 761. Overall, the risk of death was higher in patients that developed AKI during ICPI treatment [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.05-1.92, P = 0.02; heterogeneity χ
2 = 11.68, I2 = 66%, P = 0.02] compared with patients that did not develop AKI. In addition, there was a trend to a better survival in those with less severe AKI patients compared with those with more severe AKI (HR 1.35, 95% CI 0.99-1.83, P = 0.05). Lastly, it was seen that patients with persistent kidney dysfunction (non-recovery) had an increased risk for all-cause mortality (HR 2.93, 95% CI 1.41-6.08, P = 0.004; heterogeneity χ2 = 0.53, I2 = 0%, P = 0.47)., Conclusions: Development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality., Competing Interests: M.K. is member of the CKJ editorial board. A.O. is the previous CKJ Editor-in-Chief. The other authors declare that they have no conflict of interest., (© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.)- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.